Growth Hormone Releasing Factor Analog class drugs
1 result
Egrifta sv (tesamorelin)
(tesamorelin)Theratechnologies Inc.
Usage: EGRIFTA SV is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It is not intended for weight loss management and long-term cardiovascular safety is not established. Treatment continuation should be evaluated for those not experiencing a reduction in visceral adipose tissue.